Status:
COMPLETED
Rosacea and Ivermectin
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
Galderma R&D
Conditions:
Rosacea
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The primary hypothesis is that weekly digital interactions and routine measurement of TEWL rates and SC hydration levels will promote patient adherence to maintenance ivermectin therapy and prevent di...
Detailed Description
Subjects will be offered an opportunity to participate in the study. Subjects will either have a diagnosis of rosacea. A total of 30 subjects will be enrolled. After consent and basic demographics, a ...
Eligibility Criteria
Inclusion
- Subject is 18 years of age or older.
- Subject has a working knowledge of English.
- Subject with a diagnosis of Rosacea
- Subjects without a known allergy to ivermectin
- Subjects with access to a smart phone
Exclusion
- Subjects under 18 years of age.
- Subject does not have a working knowledge of English.
- Subject with a diagnosed skin condition other than rosacea
- Subjects with a known allergy to ivermectin
- Subjects without access to a smart phone
Key Trial Info
Start Date :
April 16 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 17 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04275999
Start Date
April 16 2021
End Date
January 17 2025
Last Update
November 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest Health Sciences Dermatology
Winston-Salem, North Carolina, United States, 27104